HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The combination of Astragalus membranaceus extract and ligustrazine to improve the inflammation in rats with thrombolytic cerebral ischemia.

Abstract
The purpose of the study was to evaluate the effect of Astragalus membranaceus extract and ligustrazine combination on ameliorating inflammation in cerebral ischemic rats that have undergone thrombolysis. Astragalus membranaceus and ligustrazine per se, or a combination of A. membranaceus and ligustrazine was administered by intraperitoneal injection immediately after surgery and sham surgery. After the induction of thrombolysis, the neurological function was measured and cerebral lesion volume was determined. The regulatory T cells in the spleen were measured by flow cytometry. To explore the protective effects of the combination drug on the neurological function and inflammation, the expression of transcription factor Foxp3 and cytokines, including transforming growth factor beta 1, interleukin 10, interleukin 4, interleukin 1 beta, interferon gamma, interleukin 17, in damaged brain was examined using reverse transcription polymerase chain reaction, Western blot, and enzyme-linked immunosorbent assay. The cerebral lesion volume was markedly reduced in the combination drug-treated rats compared to the rats treated with either A. membranaceus or ligustrazine alone (P < 0.05). The neurological function, regulatory T cells, transcription factor Foxp3, transforming growth factor beta 1, interleukin 10, and interleukin 4 were markedly elevated in the rats treated with combination drugs (P < 0.05). The expression of interleukin 1 beta, interferon gamma, and interleukin 17 was reduced in the rats treated with combination drug therapy (P < 0.05). Treatment with a combination of A. membranaceus and ligustrazine can ameliorate inflammation after thrombolysis and regulate the related cytokines by elevating the expression of endogenous regulatory T cells.
AuthorsRuihuan Pan, Mingchao Zhou, Yiping Zhong, Jingping Xie, Shanshan Ling, Xialin Tang, Yan Huang, Hongxia Chen
JournalInternational journal of immunopathology and pharmacology (Int J Immunopathol Pharmacol) 2019 Jan-Dec Vol. 33 Pg. 2058738419869055 ISSN: 2058-7384 [Electronic] England
PMID31409163 (Publication Type: Journal Article)
Chemical References
  • Cytokines
  • Fibrinolytic Agents
  • Plant Extracts
  • Pyrazines
  • tetramethylpyrazine
Topics
  • Animals
  • Astragalus propinquus (chemistry)
  • Brain Ischemia (drug therapy, metabolism)
  • Cerebral Infarction (drug therapy, metabolism)
  • Cytokines (metabolism)
  • Disease Models, Animal
  • Drug Therapy, Combination (methods)
  • Fibrinolytic Agents (pharmacology)
  • Inflammation (drug therapy, metabolism)
  • Male
  • Plant Extracts (pharmacology)
  • Pyrazines (pharmacology)
  • Rats
  • Rats, Wistar
  • T-Lymphocytes, Regulatory (drug effects, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: